GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (OTCPK:SHIEF) » Definitions » Debt-to-EBITDA

SHIEF (Shield Therapeutics) Debt-to-EBITDA : -0.76 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shield Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shield Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.29 Mil. Shield Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $19.68 Mil. Shield Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2024 was $-26.17 Mil. Shield Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.76.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Shield Therapeutics's Debt-to-EBITDA or its related term are showing as below:

SHIEF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.72   Med: -0.06   Max: 0.03
Current: -0.61

During the past 10 years, the highest Debt-to-EBITDA Ratio of Shield Therapeutics was 0.03. The lowest was -0.72. And the median was -0.06.

SHIEF's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs SHIEF: -0.61

Shield Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Shield Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Debt-to-EBITDA Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 -0.01 -0.16 -0.67

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.11 -0.27 -0.52 -0.76

Competitive Comparison of Shield Therapeutics's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shield Therapeutics's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Debt-to-EBITDA falls into.



Shield Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shield Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.214 + 20.031) / -30.288
=-0.67

Shield Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.292 + 19.679) / -26.168
=-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Shield Therapeutics  (OTCPK:SHIEF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Shield Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines